Q2 2022 EPS Estimates for Compugen Ltd. Raised by Analyst (NASDAQ:CGEN)

Compugen Ltd. (NASDAQ:CGEN – Get Rating) – SVB Leerink raised their Q2 2022 earnings estimates for Compugen in a research note issued on Tuesday, May 17th. SVB Leerink analyst D. Graybosch now anticipates that the biotechnology company will post earnings per share of ($0.11) for the quarter, up from their prior forecast of ($0.13). SVB Leerink has a “Outperform” rating and a $9.00 price target on the stock. SVB Leerink also issued estimates for Compugen’s Q3 2022 earnings at ($0.11) EPS, Q4 2022 earnings at ($0.15) EPS, FY2022 earnings at ($0.49) EPS, Q1 2023 earnings at ($0.13) EPS, Q2 2023 earnings at ($0.13) EPS, Q3 2023 earnings at ($0.12) EPS, Q4 2023 earnings at ($0.20) EPS, FY2023 earnings at ($0.57) EPS, FY2024 earnings at ($0.98) EPS, FY2025 earnings at ($1.87) EPS and FY2026 earnings at ($1.49) EPS.

Compugen (NASDAQ:CGEN – Get Rating) last posted its earnings results on Monday, May 16th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. During the same quarter in the previous year, the company posted ($0.12) earnings per share.

A number of other equities research analysts also recently issued reports on CGEN. Oppenheimer lowered their price target on shares of Compugen from $17.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, February 25th. Zacks Investment Research downgraded shares of Compugen from a “buy” rating to a “hold” rating in a report on Wednesday, April 27th. Finally, StockNews.com cut Compugen from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $11.13.

Shares of CGEN opened at $1.93 on Thursday. Compugen has a 52-week low of $1.66 and a 52-week high of $9.20. The stock’s 50-day simple moving average is $2.73 and its 200 day simple moving average is $3.67.

Hedge funds have recently added to or reduced their stakes in the stock. Bridgefront Capital LLC bought a new stake in Compugen in the third quarter valued at approximately $61,000. Invesco Ltd. bought a new stake in shares of Compugen during the 2nd quarter valued at $92,000. Virtu Financial LLC purchased a new stake in shares of Compugen in the 1st quarter worth about $37,000. Oppenheimer & Co. Inc. purchased a new position in Compugen during the 4th quarter valued at about $49,000. Finally, Walleye Trading LLC bought a new stake in Compugen during the fourth quarter worth about $55,000.

About Compugen (Get Rating)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.

See Also